Evgen Pharma PLC Poster Presentation of SFX-01 Mechanistic Data (8094B)
15 January 2018 - 6:00PM
UK Regulatory
TIDMEVG
RNS Number : 8094B
Evgen Pharma PLC
15 January 2018
For immediate release 15 January 2018
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Poster presentation of SFX-01 stem cell data in breast
cancer
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce that the results of mechanistic
studies into SFX-01, the Company's lead compound, in breast cancer
are being presented this afternoon in a poster at the UK
Interdisciplinary Breast Cancer Symposium 2018, Manchester.
The studies used patient samples and patient-derived tumour
models to show that SFX-01 targets cancer stem cells ("CSC") in
early and metastatic breast cancers and has the potential to
overcome resistance to endocrine treatment in oestrogen-receptor
positive ("ER+") breast cancers.
The studies also showed that SFX-01 potently suppressed the
elevated levels of phospho-STAT3 ("STAT3") seen after endocrine
treatment. Investigations are continuing into the role of STAT3
signalling effectors as part of this mechanism of action.
The poster, entitled SFX-01 targets STAT3 signalling to inhibit
stem-like cells in breast cancer patient-derived xenograft tumours,
concludes that the study data "demonstrate the potential of SFX-01
for clinically meaningful improvements to endocrine therapy in ER+
breast cancer by reversing CSC-mediated resistance".
The lead authors of the poster are Dr Bruno Simões and Dr Rob
Clarke. Dr Clarke, who led the studies, is a Reader in Breast
Biology and is the Director of the Manchester Breast Cancer Now
Research Unit at the University of Manchester.
A copy of the poster will be made available later today on Evgen
Pharma's website, www.evgen.com.
Steve Franklin, CEO of Evgen Pharma, said:
"We are very excited by this data, which provides further
evidence that SFX-01's mechanism of action is to target cancer stem
cells to reverse the resistance to hormone treatment seen in ER+
breast cancer. I would like to thank Dr Clarke and his team for
their on-going work on SFX-01. The team's work highlights the
effect of SFX-01 on STAT3, which is well known to play a key role
in tumour renewal and metastases.
"This mechanistic work supports our on-going Phase II clinical
trial of SFX-01 in metastatic breast cancer patients. We look
forward to reporting an interim update from the Phase II trial in
the first half of this calendar year followed by the final read-out
around the year-end."
Further details of the UK Interdisciplinary Breast Cancer
Symposium 2018, 15-16 January 2018, are available at this link:
http://breastcancerconference.org/
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
Dr Stephen Franklin, CEO 5000
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Stephanie +44 (0) 20 7466
Watson 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney
(Corporate Finance)
John Howes, Rob Rees (Corporate +44 (0) 20 3861
Broking) 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFKQDQDBKBDDD
(END) Dow Jones Newswires
January 15, 2018 02:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024